Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Obatoclax Mesylate (GX15-070) Chemical Structure

Obatoclax Mesylate (GX15-070) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

9 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Obatoclax Mesylate (GX15-070) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Pan Bcl-2 Inhibitor

    ABT-737 Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

  • Most Potent Bcl-2 Inhibitor

    ABT-263 (Navitoclax) Bcl-xL, Ki≤ 0.5 nM; Bcl-2, Ki≤ 1 nM; Bcl-w, Ki≤ 1 nM.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area

Product Description

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Targets Bcl-2 [1]
(Cell-free assay)
IC50 0.22 μM(Ki)
In vitro Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KARPAS-45MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnldG9SUUN3ME2wMlAxODB|MUeg{txOMn73V2FPT0WU
SK-MEL-30NVG4UHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\ZV3R[UUN3ME2wMlAxODN3NTFOwG0>NXLKT3htW0GQR1XS
NALM-6M4eyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD2TWM2OD1yLkCwNFM2PiEQvF2=M2T0S3NCVkeHUh?=
KYSE-450MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;oTWM2OD1yLkCwNFQ3QSEQvF2=M1\xfXNCVkeHUh?=
BHYNXfjSWk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkD5TWM2OD1yLkCwNFYxOSEQvF2=MoHFV2FPT0WU
GR-STM3z2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[0XlhKSzVyPUCuNFAxPjR6IN88US=>MUjTRW5ITVJ?
786-0MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljHTWM2OD1yLkCwNFc4PiEQvF2=NX3GdpFSW0GQR1XS
C-33-ANGPYOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\3W2JKSzVyPUCuNFAxQDR6IN88US=>MkPpV2FPT0WU
BHT-101NGDPOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTLbGlKSzVyPUCuNFAyODZizszNMkTGV2FPT0WU
EB2M{fmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXyTWM2OD1yLkCwNVE5KM7:TR?=MWjTRW5ITVJ?
G-361NYrzc2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLVTWM2OD1yLkCwNVI1KM7:TR?=M{fpNXNCVkeHUh?=
KE-37NUiyelJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMECxNlgh|ryPMV;TRW5ITVJ?
MHH-PREB-1M{HZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIn5OVlKSzVyPUCuNFAyPCEQvF2=MUnTRW5ITVJ?
MCF7MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTBwMECxOVkh|ryPMkHqV2FPT0WU
LOUCYNEfmZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYP2eHZXUUN3ME2wMlAxOTd3IN88US=>M{nIUnNCVkeHUh?=
EW-7NH;l[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjxVVRnUUN3ME2wMlAxOTd3IN88US=>M1LLbnNCVkeHUh?=
KYSE-510NEPSNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonITWM2OD1yLkCwNlM{KM7:TR?=M1vmN3NCVkeHUh?=
SK-MEL-3M1HBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LhdWlEPTB;MD6wNFI3PCEQvF2=MlXIV2FPT0WU
HAL-01MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHPTWM2OD1yLkCwNlk4KM7:TR?=MmKwV2FPT0WU
HCC2998NFm3VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nSZmlEPTB;MD6wNFM{PSEQvF2=NGXHbGtUSU6JRWK=
A375M1PTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\1U2lEPTB;MD6wNFM2KM7:TR?=MVvTRW5ITVJ?
MZ7-melMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwMECzPVkh|ryPNYG4XJExW0GQR1XS
SH-4M2[5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\HWVdKSzVyPUCuNFA1OTdizszNM3LoTXNCVkeHUh?=
HT-144NES2TZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPVS5RKSzVyPUCuNFA1OyEQvF2=NWL0NFh{W0GQR1XS
KYSE-140NYHrPZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzsTno{UUN3ME2wMlAxPDN3IN88US=>NFHLSZRUSU6JRWK=
PSN1MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NED2dIVKSzVyPUCuNFA1PjdizszNMYrTRW5ITVJ?
COLO-679M2LGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmO2TWM2OD1yLkCwOFk5KM7:TR?=M2Tu[3NCVkeHUh?=
SW620NI[3S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwMEC1NVEh|ryPNXTUR3pkW0GQR1XS
HGC-27MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHHfXlKSzVyPUCuNFA2OjRizszNNYHGT5ZnW0GQR1XS
IGROV-1MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;nSmlEPTB;MD6wNFYh|ryPMnPDV2FPT0WU
IGR-1NYHUU4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHOXG1KSzVyPUCuNFA3ODFizszNMUjTRW5ITVJ?
EW-1NISwXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjYOJpKUUN3ME2wMlAxPjVzIN88US=>NVLmbZppW0GQR1XS
769-PMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTBwMEC2O|gh|ryPM4DMfHNCVkeHUh?=
HNM2\OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELGSXZKSzVyPUCuNFA3PzlizszNM1O5bXNCVkeHUh?=
SIG-M5M1HxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXXXIdKSzVyPUCuNFA4OSEQvF2=MYTTRW5ITVJ?
IST-MEL1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7r[YpKSzVyPUCuNFA5OThizszNNGjqPWpUSU6JRWK=
ST486M4H6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPaTWM2OD1yLkCwPFI2KM7:TR?=NWXJ[HV6W0GQR1XS
ES7MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7vTWM2OD1yLkCwPFQ3KM7:TR?=MXnTRW5ITVJ?
GAKNWDYV4JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTBwMEC4OFgh|ryPNY\xVnllW0GQR1XS
BB30-HNCMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHS[3BKSzVyPUCuNFA5PThizszNNYr5[3k2W0GQR1XS
IPC-298NVn2emZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPxZWp4UUN3ME2wMlAxQTJ5IN88US=>NFToOm5USU6JRWK=
NKM-1M2PUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XHOGlEPTB;MD6wNFk4OiEQvF2=MnLzV2FPT0WU
RKOMmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\HTWM2OD1yLkCxNFQ1KM7:TR?=MXzTRW5ITVJ?
ACNMmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3e5e2lEPTB;MD6wNVE{OSEQvF2=NEjJNIVUSU6JRWK=
SW1417MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TT[mlEPTB;MD6wNVIzPSEQvF2=NYL4RoFCW0GQR1XS
SRMkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXSOVY1UUN3ME2wMlAyOjN3IN88US=>MorhV2FPT0WU
SNG-MNVzWdmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTBwMEGzNVch|ryPM165d3NCVkeHUh?=
CAL-12TMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXuzNphuUUN3ME2wMlAyOzR4IN88US=>MkDFV2FPT0WU
HSC-3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTBwMEGzOVUh|ryPNYrNbWplW0GQR1XS
DOHH-2NXPiNoRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XG[mlEPTB;MD6wNVQyOiEQvF2=M1niTXNCVkeHUh?=
NB69NYju[49rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfITWM2OD1yLkCxOVY2KM7:TR?=M1\Vc3NCVkeHUh?=
LC-2-adNGPt[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vaUmlEPTB;MD6wNVU5OSEQvF2=Mn33V2FPT0WU
RVH-421MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwMEG2O|Qh|ryPMoXqV2FPT0WU
TGWNX\tN|hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPlVpU1UUN3ME2wMlAyPzN7IN88US=>NF3JPHFUSU6JRWK=
HCC1569MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjSOJhKSzVyPUCuNFE4QTdizszNNEew[GlUSU6JRWK=
CAL-85-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTBwMEG4N|Ih|ryPM2f4THNCVkeHUh?=
RPMI-8402M3nxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojMTWM2OD1yLkCxPFU5KM7:TR?=NEHJbnhUSU6JRWK=
THP-1NV7SRYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPQTWM2OD1yLkCxPVk5KM7:TR?=M4exbHNCVkeHUh?=
ONS-76NFr2dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHG3T5lKSzVyPUCuNFIxOzZizszNMWHTRW5ITVJ?
A2780Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwMEKwO|kh|ryPNW\OOlBnW0GQR1XS
RPMI-2650NVXCcm5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlr1TWM2OD1yLkCyNlk3KM7:TR?=MW\TRW5ITVJ?
MEL-HOM123cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTBwMEKzOFgh|ryPM{XIT3NCVkeHUh?=
MC-CARMkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTBwMEKzOVYh|ryPNWThcnpPW0GQR1XS
HSC-2NUL1UZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rvU2lEPTB;MD6wNlQ3PiEQvF2=NWX3NnBJW0GQR1XS
MEL-JUSOMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fMOmlEPTB;MD6wNlQ4OyEQvF2=NYrsNopMW0GQR1XS
CAL-62NFS5W|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LS[GlEPTB;MD6wNlYxOiEQvF2=MkLQV2FPT0WU
DMS-273MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jjWWlEPTB;MD6wNlg1PyEQvF2=NHS0bolUSU6JRWK=
S-117NEn3eZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlq0TWM2OD1yLkCyPVA3KM7:TR?=NVjUc|Z[W0GQR1XS
SUP-T1NHe1PWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnDcVJKSzVyPUCuNFI6PDlizszNMYfTRW5ITVJ?
MZ2-MELM2r0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrVTWM2OD1yLkCyPVU6KM7:TR?=MlTwV2FPT0WU
KYSE-270MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnr3TWM2OD1yLkCyPVc3KM7:TR?=NIfY[ZRUSU6JRWK=
CMKNHPRT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3mOXB[UUN3ME2wMlA{ODJ|IN88US=>MXrTRW5ITVJ?
8505CMmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\wTWM2OD1yLkCzNFQh|ryPMX\TRW5ITVJ?
NUGC-3M3nwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXGTWM2OD1yLkCzNFQ5KM7:TR?=NXO1Vnp{W0GQR1XS
A101DNHvOc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MomwTWM2OD1yLkCzNFU2KM7:TR?=M2TKenNCVkeHUh?=
G-401NELB[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwMEOwPVMh|ryPMnjsV2FPT0WU
OVCAR-8NWDEeVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LVWGlEPTB;MD6wN|ExPyEQvF2=MUfTRW5ITVJ?
IMR-5NWL4VY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTBwMEOyOFQh|ryPM1XpNHNCVkeHUh?=
DoTc2-4510MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DJSmlEPTB;MD6wN|M6OyEQvF2=MYfTRW5ITVJ?
HOSMl\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHnfnNKSzVyPUCuNFM1PzNizszNMlj3V2FPT0WU
HEC-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfHUJpKSzVyPUCuNFM3QCEQvF2=M2\GVXNCVkeHUh?=
SW756NXrQSHF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O1NmlEPTB;MD6wN|gzOSEQvF2=NGGzcotUSU6JRWK=
NCI-H64Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2e2Z2lEPTB;MD6wN|g1OiEQvF2=MmrIV2FPT0WU
EW-16M160Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVH0TYV4UUN3ME2wMlA{QTB7IN88US=>MVXTRW5ITVJ?
CAL-51NYHCdZU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\3TWlEPTB;MD6wOFAxPSEQvF2=NHzObXZUSU6JRWK=
KYSE-150NE\ncVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvsZ2pjUUN3ME2wMlA1ODFzIN88US=>NYHD[olDW0GQR1XS
SW1710NIHRO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfRV3JKSzVyPUCuNFQxOThizszNNWPUNpFwW0GQR1XS
HuP-T4NUnlbIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDYZnVKSzVyPUCuNFQyOThizszNMX;TRW5ITVJ?
LB373-MEL-DNH7oRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTBwMESyN|Ih|ryPNELt[FZUSU6JRWK=
EW-13NEXBcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTBwMES0NFYh|ryPNXns[Gt7W0GQR1XS
HT-29MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\qTWM2OD1yLkC0OFkh|ryPMoTLV2FPT0WU
SCC-25MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTBwMES0PVQh|ryPMULTRW5ITVJ?
REHNU\wUVBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nJOWlEPTB;MD6wOFY{PSEQvF2=M4XGW3NCVkeHUh?=
L-363M{j3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3GyUmlEPTB;MD6wOFY4QSEQvF2=MmHUV2FPT0WU
NCI-H1770MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwMES2PVch|ryPNFHkNoFUSU6JRWK=
CHL-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Hj[GlEPTB;MD6wOFg2PyEQvF2=MWfTRW5ITVJ?
ES1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;QWHNKSzVyPUCuNFQ5QDVizszNNHXBWYtUSU6JRWK=
SCC-15NFPXcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zu[WlEPTB;MD6wOFkxOiEQvF2=NXXsUHN[W0GQR1XS
MRK-nu-1NGna[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULXRXloUUN3ME2wMlA1QTN4IN88US=>MX\TRW5ITVJ?
PF-382MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMES5N|kh|ryPMUTTRW5ITVJ?
COLO-680NNE\SUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEC5VnBKSzVyPUCuNFUxPDdizszNMomyV2FPT0WU
LK-2NGLabJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETtNW5KSzVyPUCuNFUxPjNizszNM3zQNnNCVkeHUh?=
NCI-H2342NVq2c4RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnG2TWM2OD1yLkC1NVE4KM7:TR?=M2nXRXNCVkeHUh?=
HMV-IINWDPSZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWwZpFKSzVyPUCuNFUzOzlizszNMXjTRW5ITVJ?
PC-14MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDicJJKSzVyPUCuNFUzPTJizszNMn3QV2FPT0WU
COLO-320-HSRNXv0do1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwMEWyPFkh|ryPMlfhV2FPT0WU
697NUXCb|VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTLTWM2OD1yLkC1N|I{KM7:TR?=MYTTRW5ITVJ?
NEC8M{POPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PEb2lEPTB;MD6wOVU6KM7:TR?=M4fZcHNCVkeHUh?=
LCLC-97TM1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX6VXlzUUN3ME2wMlA2PTl2IN88US=>MnvOV2FPT0WU
DaoyM{m0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwMEW2NVYh|ryPNVjJWmpFW0GQR1XS
ETK-1NH7VZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Sw[2lEPTB;MD6wOVY4OiEQvF2=NEn5RW1USU6JRWK=
A388MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rvVmlEPTB;MD6wOVY6PSEQvF2=MnvFV2FPT0WU
COLO-205Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PKNmlEPTB;MD6wOVcyPiEQvF2=NHy5N45USU6JRWK=
SK-PN-DWM1KxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHWxcVJKSzVyPUCuNFU4OjlizszNNX;zWoJqW0GQR1XS
SF268NX:5W485T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHm[5NKSzVyPUCuNFU4PTZizszNM3ntcHNCVkeHUh?=
OCI-AML2MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;FSG5KSzVyPUCuNFU4PzdizszNMYDTRW5ITVJ?
GAMGM1vaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvaXo53UUN3ME2wMlA2QCEQvF2=MWHTRW5ITVJ?
BCPAPMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTBwMEW4PVIh|ryPMlm3V2FPT0WU
BC-1M3fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWK0PVNJUUN3ME2wMlA3ODJ{IN88US=>Ml31V2FPT0WU
IA-LMMlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTBwME[wOVMh|ryPM2roWnNCVkeHUh?=
NCI-H1299NV7Gc5dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHQTGtKSzVyPUCuNFYyOyEQvF2=M{jDbHNCVkeHUh?=
COR-L23Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwME[xN|Qh|ryPMnvZV2FPT0WU
KYSE-180NGDlN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn22TWM2OD1yLkC2NVQzKM7:TR?=MWXTRW5ITVJ?
LOXIMVIMmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIixXotKSzVyPUCuNFYyQDhizszNNUn6cYp5W0GQR1XS
BL-41NIWxVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFr6U|hKSzVyPUCuNFYzOTlizszNMoniV2FPT0WU
BL-70M{XIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2C2VGlEPTB;MD6wOlMxOiEQvF2=MYjTRW5ITVJ?
NOS-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTOUXhKSzVyPUCuNFY1OTFizszNNIfIXGFUSU6JRWK=
NB13M1jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nCbmlEPTB;MD6wOlQzOSEQvF2=MYrTRW5ITVJ?
CAL-27MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\CTWM2OD1yLkC2OFY1KM7:TR?=MV\TRW5ITVJ?
CA46NFvXOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTBwME[1N|ch|ryPMojZV2FPT0WU
SW962MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnsTWM2OD1yLkC2OVY6KM7:TR?=M3W0SXNCVkeHUh?=
NCI-H226NXzVdHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NED2PZRKSzVyPUCuNFY3OzJizszNMojxV2FPT0WU
KYSE-70MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnaSppKSzVyPUCuNFY6PDVizszNMXjTRW5ITVJ?
DaudiNYflXFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjaTWM2OD1yLkC3NFgyKM7:TR?=MmHiV2FPT0WU
SW626NVPKW5NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTVOVZJUUN3ME2wMlA4OjB2IN88US=>M1jCUXNCVkeHUh?=
ESS-1MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTBwMEeyOFYh|ryPMn;6V2FPT0WU
YTM1u0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;nTWM2OD1yLkC3N|Q2KM7:TR?=NG[5TW9USU6JRWK=
P12-ICHIKAWAM4DSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnqzTWM2OD1yLkC3N|Q6KM7:TR?=NIXGZpdUSU6JRWK=
BxPC-3NF24SY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPvS|dKSzVyPUCuNFc1PThizszNNWnUS3RsW0GQR1XS
CTV-1NUWzUoluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXywZmp1UUN3ME2wMlA4PTF5IN88US=>MVnTRW5ITVJ?
MLMAM3;uNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzWe|hKSzVyPUCuNFc2OzRizszNMVPTRW5ITVJ?
WSU-NHLMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfpNYNKSzVyPUCuNFc2PTRizszNNVX3WVE5W0GQR1XS
CTB-1NGTJcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHOcY1KSzVyPUCuNFc2QDhizszNM4C5WnNCVkeHUh?=
MMAC-SFNEjTVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXUTWM2OD1yLkC3OlY5KM7:TR?=Ml:0V2FPT0WU
8-MG-BANGe4eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPC[WpKSzVyPUCuNFc5ODFizszNMoHyV2FPT0WU
NCI-H358MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3XVlBKSzVyPUCuNFc5PzlizszNNELPSlFUSU6JRWK=
BFTC-905MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjGTWM2OD1yLkC3PVA6KM7:TR?=MVfTRW5ITVJ?
NCI-H727NV;JOHdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjL[5pKSzVyPUCuNFgxPTNizszNNVf0[ppiW0GQR1XS
CHP-212Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLpTWM2OD1yLkC4NFk2KM7:TR?=Mlq2V2FPT0WU
HOP-62M{XGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwMEiyOFUh|ryPNH:0e4NUSU6JRWK=
CESSMlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTtTGJKSzVyPUCuNFgzPjlizszNM17NWnNCVkeHUh?=
HuCCT1M3fW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nEZmlEPTB;MD6wPFM{OyEQvF2=MVHTRW5ITVJ?
DELM2jRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\DTWM2OD1yLkC4N|Q4KM7:TR?=NEjzOHFUSU6JRWK=
5637M4rJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3i1bWlEPTB;MD6wPFM3PyEQvF2=M4[0enNCVkeHUh?=
RS4-11MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjNcVBKSzVyPUCuNFg1QTdizszNMUPTRW5ITVJ?
KURAMOCHINUfFfJNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S3OWlEPTB;MD6wPFUxQSEQvF2=MV\TRW5ITVJ?
A427NF;wcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjsTWM2OD1yLkC4OVEzKM7:TR?=M4nxeXNCVkeHUh?=
A3-KAWMlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mor2TWM2OD1yLkC4OVY3KM7:TR?=Ml63V2FPT0WU
LS-123M{\0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoniTWM2OD1yLkC4O|E6KM7:TR?=M2nJb3NCVkeHUh?=
LoVoMlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1r5d2lEPTB;MD6wPFczKM7:TR?=Mk\wV2FPT0WU
PA-1Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M375Z2lEPTB;MD6wPFc3QSEQvF2=M3;qdXNCVkeHUh?=
CP50-MEL-BNXW2e4lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTjcJdIUUN3ME2wMlA5Pzl|IN88US=>NEPZRZNUSU6JRWK=
A431MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTBwMEi4NFEh|ryPMX\TRW5ITVJ?
HCT-116Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LPfGlEPTB;MD6wPFgxOiEQvF2=NUDSPYpRW0GQR1XS
A4-FukMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwMEi5OFch|ryPNFfkeFhUSU6JRWK=
RPMI-6666MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwMEi5Olch|ryPNHvBenpUSU6JRWK=
Calu-6NUHrb2x{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTBwMEmwNlkh|ryPMU\TRW5ITVJ?
KMOE-2NIfWbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHRTWM2OD1yLkC5NFM6KM7:TR?=NF\ReplUSU6JRWK=
A704MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTBwMEmxOUDPxE1?MoPqV2FPT0WU
HO-1-N-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkWxTWM2OD1yLkC5NlQ6KM7:TR?=M3HJPHNCVkeHUh?=
NCI-H2122NVPvZlJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3qyOWlEPTB;MD6wPVM4QCEQvF2=NHLMNY9USU6JRWK=
U-698-MNGPPUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nscmlEPTB;MD6wPVQxQSEQvF2=NFruTGRUSU6JRWK=
IST-SL2NETDU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXEcZhWUUN3ME2wMlA6PDZ6IN88US=>NEHX[lNUSU6JRWK=
TE-10NFHUUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TKOGlEPTB;MD6wPVU5PCEQvF2=MmHTV2FPT0WU
PANC-03-27MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\hdIZKSzVyPUCuNFk3PzFizszNMkfOV2FPT0WU
KYSE-410NIPpXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DzR2lEPTB;MD6wPVc6PyEQvF2=M2jQbHNCVkeHUh?=
TE-8MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\FXGxYUUN3ME2wMlA6QDh3IN88US=>MXPTRW5ITVJ?
MN-60MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjqdnNoUUN3ME2wMlA6QDl5IN88US=>MXPTRW5ITVJ?
NCI-H460M3f4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTBwMUCwPUDPxE1?MkfWV2FPT0WU
LB771-HNCMoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHNT3lKSzVyPUCuNVAzPTVizszNNWfId21CW0GQR1XS
ES4NEX4coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTBwMUCyOlQh|ryPMoqyV2FPT0WU
HUTU-80M1L2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;aU413UUN3ME2wMlExOzZ3IN88US=>NF\vfIlUSU6JRWK=
647-VNYfjfGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\jTWM2OD1yLkGwOFA5KM7:TR?=MlXEV2FPT0WU
HTC-C3MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;0cXpKSzVyPUCuNVA1OzJizszNNGPuVINUSU6JRWK=
NTERA-S-cl-D1NVnvOpo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzDd|lKSzVyPUCuNVA1PDhizszNNEfXPGtUSU6JRWK=
A2058NFvFfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfSSYVjUUN3ME2wMlExPjV3IN88US=>MkH3V2FPT0WU
MZ1-PCM4rIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDyZmNWUUN3ME2wMlExQDNizszNMYfTRW5ITVJ?
J82MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHxTWM2OD1yLkGwPFg1KM7:TR?=NIrRTFhUSU6JRWK=
ARH-77MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvON45KSzVyPUCuNVEh|ryPNGHYVVdUSU6JRWK=
Ca9-22NHzXbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTBwMUGxNlgh|ryPMn6yV2FPT0WU
NCI-H1648NGDBPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTBwMUGyPFYh|ryPNHjpeVhUSU6JRWK=
MC116NF35T4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwMUGzN|ch|ryPNUn4Tos3W0GQR1XS
EoL-1-cellMnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjCVFJ4UUN3ME2wMlEyPDZ5IN88US=>M17jdXNCVkeHUh?=
PANC-10-05NGnRU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTDT2JKSzVyPUCuNVE1QTFizszNM4Doe3NCVkeHUh?=
SF539M2rhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTWTWM2OD1yLkGxOlE3KM7:TR?=MXvTRW5ITVJ?
ES8NWPodnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1roO2lEPTB;MD6xNVY{OyEQvF2=MX\TRW5ITVJ?
NCI-H810M2DnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwMUG2OlQh|ryPNUfyUpZ6W0GQR1XS
J-RT3-T3-5NEHFZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTBUnBrUUN3ME2wMlEyPzVizszNNXOyWplVW0GQR1XS
NYNFrwXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPxNVFKSzVyPUCuNVE5OTdizszNMlm1V2FPT0WU
NCI-SNU-1MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHMWFAzUUN3ME2wMlEzOTR6IN88US=>Mk[yV2FPT0WU
EFM-19NWLYelVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnSPVZKSzVyPUCuNVI{PzRizszNMY\TRW5ITVJ?
HCC1806MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PhcGlEPTB;MD6xNlM5OyEQvF2=MXjTRW5ITVJ?
HCE-TNGX5OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPVOm1KSzVyPUCuNVI2OzFizszNNV\HcZhEW0GQR1XS
HT-1376NU\vdoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHf6UHFKSzVyPUCuNVI3PjhizszNMnnBV2FPT0WU
BE-13MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYn4V2x7UUN3ME2wMlEzQDZ4IN88US=>M2DhbnNCVkeHUh?=
NCI-H520MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlyzTWM2OD1yLkGyPFY4KM7:TR?=MmDPV2FPT0WU
SK-MES-1M3f2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4OzS2lEPTB;MD6xNlkyOyEQvF2=MoP2V2FPT0WU
SNU-423MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjLTWM2OD1yLkGyPVE1KM7:TR?=MXPTRW5ITVJ?
Ramos-2G6-4C10MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf6R4wzUUN3ME2wMlEzQTF4IN88US=>NGTFVXpUSU6JRWK=
EW-18MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH1TWM2OD1yLkGzNFI3KM7:TR?=MYTTRW5ITVJ?
NCI-H2087Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPqTWM2OD1yLkGzNFI4KM7:TR?=M1jEfHNCVkeHUh?=
COLO-792NUnDV5J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTBXox7UUN3ME2wMlE{OTZ3IN88US=>M3LXc3NCVkeHUh?=
QIMR-WILNUn0PWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrJTWM2OD1yLkGzNlI{KM7:TR?=NHq5WopUSU6JRWK=
ACHNNXzvTFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTBwMUOyOFch|ryPNFHFbItUSU6JRWK=
RPMI-8866MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHIZW5KSzVyPUCuNVMzPjFizszNMUHTRW5ITVJ?
SK-LU-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4i0U2lEPTB;MD6xN|Q1QSEQvF2=MlXqV2FPT0WU
SK-UT-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7UOZNrUUN3ME2wMlE{PjJ6IN88US=>M4LmVHNCVkeHUh?=
MFE-296MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTBcIZ7UUN3ME2wMlE{QDZ2IN88US=>M2\mT3NCVkeHUh?=
RDNX\BWG11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHCTWM2OD1yLkGzPVk4KM7:TR?=NVrTdlA2W0GQR1XS
LS-411NNFnDVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjteFVpUUN3ME2wMlE1Ojl3IN88US=>MXrTRW5ITVJ?
NCI-H747NHjGUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTBwMUSzJO69VQ>?NX3IO2dDW0GQR1XS
ES6M{\lOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVqze3p6UUN3ME2wMlE1OzZizszNNVzGOmdtW0GQR1XS
TE-1M{Pj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HOZmlEPTB;MD6xOFQxPyEQvF2=NEDIOHZUSU6JRWK=
SJSA-1NX;nXoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrBOWtQUUN3ME2wMlE1PzB5IN88US=>NYLiPW97W0GQR1XS
NCI-H1355M3n4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfoZXFJUUN3ME2wMlE2Ojl|IN88US=>MV3TRW5ITVJ?
HELNWnzT3o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjQdGVmUUN3ME2wMlE2PDR5IN88US=>MYnTRW5ITVJ?
639-VM2\TXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Hre2lEPTB;MD6xOVU6PiEQvF2=M3znc3NCVkeHUh?=
AN3-CAM33hWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwMUW2N|kh|ryPNHvuOINUSU6JRWK=
SK-MEL-2M{jxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v4ZmlEPTB;MD6xOVY3QCEQvF2=NF20cm1USU6JRWK=
SW872M4Ty[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XPTGlEPTB;MD6xOlA1OiEQvF2=M3PZRXNCVkeHUh?=
DU-4475NVTUVJNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjVfWFKSzVyPUCuNVYyPjJizszNNGTse3ZUSU6JRWK=
YKG-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG5TWM2OD1yLkG2Nlc{KM7:TR?=M3;jSXNCVkeHUh?=
GT3TKBMmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjxTWM2OD1yLkG2Nlg{KM7:TR?=M3G3bnNCVkeHUh?=
GB-1MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFGwUZVKSzVyPUCuNVY1OjRizszNMlvUV2FPT0WU
KARPAS-422NHrrTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3L0c2lEPTB;MD6xOlU4PCEQvF2=NUPPS4VNW0GQR1XS
ATN-1M17Nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPKbZpKSzVyPUCuNVY3PTZizszNMlnDV2FPT0WU
HLEMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoSyTWM2OD1yLkG2PFc4KM7:TR?=NXL0TXRsW0GQR1XS
D-542MGMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXkTWM2OD1yLkG2PVg3KM7:TR?=MmrRV2FPT0WU
EB-3NInEZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTBwMUezNUDPxE1?M2f5cXNCVkeHUh?=
HCC1143MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrFRW1KSzVyPUCuNVc{QTZizszNNUfYe3Q{W0GQR1XS
DJM-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMUe0OVEh|ryPMkLLV2FPT0WU
BT-474Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;HU5dKUUN3ME2wMlE4PDh7IN88US=>MWjTRW5ITVJ?
BB65-RCCM1\U[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXqNYh5UUN3ME2wMlE4PTR3IN88US=>MmrLV2FPT0WU
NCI-H292NYXJepZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLQTXBKSzVyPUCuNVc3ODFizszNM1jnOHNCVkeHUh?=
MKN28MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDrTWM2OD1yLkG3OlU{KM7:TR?=NHfLU2JUSU6JRWK=
TK10M{W4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTBwMUe3NFIh|ryPMWfTRW5ITVJ?
TYK-nuNHPPPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fSWGlEPTB;MD6xO|k1QSEQvF2=MVjTRW5ITVJ?
8305CMkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\nWmlEPTB;MD6xO|k4OSEQvF2=NWHJXY57W0GQR1XS
MV-4-11Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HwVGlEPTB;MD6xO|k4PyEQvF2=MoW2V2FPT0WU
NCI-H522NYjjeZFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnEbWtjUUN3ME2wMlE5ODl2IN88US=>NG\wPVFUSU6JRWK=
Hs-578-TNIXHOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHu3PGNKSzVyPUCuNVgzQTJizszNMVjTRW5ITVJ?
LCLC-103HNIPVSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGG1bYtKSzVyPUCuNVg2OjdizszNNWDRcXlEW0GQR1XS
MHH-ES-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLieW5KSzVyPUCuNVg3OjlizszNNE\m[2VUSU6JRWK=
NCI-H441M{\1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT0RmJKSzVyPUCuNVkyPDhizszNNWHnfpFMW0GQR1XS
AM-38MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfnSo9bUUN3ME2wMlE6OjJ3IN88US=>M4mwOXNCVkeHUh?=
SW1783NYnoTG0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGW3fpZKSzVyPUCuNVk{ODVizszNMYnTRW5ITVJ?
SK-HEP-1NILENXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXe0fXF6UUN3ME2wMlE6PjN5IN88US=>MYfTRW5ITVJ?
OAW-28NETUdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjlZlZKSzVyPUCuNlAyPzhizszNMWPTRW5ITVJ?
TE-15NYXvTmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTBwMkCyOVIh|ryPM2DCenNCVkeHUh?=
HCE-4M2\iWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vEVWlEPTB;MD6yNFI5PCEQvF2=MnTCV2FPT0WU
JiyoyeP-2003MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXzUI5wUUN3ME2wMlIxOzN4IN88US=>MX\TRW5ITVJ?
OVCAR-4MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXviW2ZYUUN3ME2wMlIxPjJ6IN88US=>M{nSXnNCVkeHUh?=
SNU-449NHPlW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33iO2lEPTB;MD6yNFc6PyEQvF2=NHe0dYJUSU6JRWK=
SBC-5NGP6b3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnflTWM2OD1yLkKxNlE2KM7:TR?=MlW5V2FPT0WU
T84NFjpTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTBwMkGyOFgh|ryPNXrQNY1UW0GQR1XS
LP-1MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTBwMkGzNFIh|ryPMkPxV2FPT0WU
MG-63NInUZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPaTWM2OD1yLkKxN|gzKM7:TR?=NH7SS3pUSU6JRWK=
OAW-42MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1yzcmlEPTB;MD6yNVQ4QCEQvF2=NH7yb5hUSU6JRWK=
L-540NWDUNotoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPaTWM2OD1yLkKxOVk5KM7:TR?=NXfmVZdKW0GQR1XS
RH-1NYCzcZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XNTmlEPTB;MD6yNlI1OiEQvF2=NH7leItUSU6JRWK=
HCT-15NXu4Tnh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnJN4JKSzVyPUCuNlI1QDRizszNMWnTRW5ITVJ?
OCUB-MM1vN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHtPYpKSzVyPUCuNlI1QDhizszNNVPPb45oW0GQR1XS
GP5dM3LO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7TTWM2OD1yLkKyOVI5KM7:TR?=NWLUWnNxW0GQR1XS
NCI-H2030NF;XUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFi3fFBKSzVyPUCuNlI4OzRizszNNWnmTVlzW0GQR1XS
ML-2MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mli2TWM2OD1yLkKyPFg6KM7:TR?=Ml7aV2FPT0WU
CAL-39MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwMkK5N|Yh|ryPNVrsZ|lCW0GQR1XS
MIA-PaCa-2M1TtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHCRoNZUUN3ME2wMlI{Ojh5IN88US=>MXPTRW5ITVJ?
TE-9NE\ufFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTWTWM2OD1yLkKzN|Ih|ryPNGHGN4JUSU6JRWK=
LB2518-MELM3PpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnKc|k3UUN3ME2wMlI{Ozd{IN88US=>Ml7mV2FPT0WU
DBNIq2bY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2n4c2lEPTB;MD6yN|Q{QCEQvF2=Mm\OV2FPT0WU
NCI-H596MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHmbppKSzVyPUCuNlM2PzFizszNM1j6R3NCVkeHUh?=
SW1990NIC3d|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DJcGlEPTB;MD6yN|k1PiEQvF2=M4fIdXNCVkeHUh?=
P30-OHKNWS5NmkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTBwMkSwOUDPxE1?M{XpUHNCVkeHUh?=
ALL-PONFKxNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPyTWM2OD1yLkK0NVY6KM7:TR?=M{HsT3NCVkeHUh?=
Saos-2NU\TPVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[5bGlEPTB;MD6yOFU4OSEQvF2=NXTPNodPW0GQR1XS
MFH-inoNWmyT25rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH[1S|lKSzVyPUCuNlQ3QTJizszNMmHWV2FPT0WU
OE33MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPjPJhKSzVyPUCuNlUyOSEQvF2=MUjTRW5ITVJ?
Calu-3NE\vZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwMkWyPVch|ryPMmjBV2FPT0WU
HTM2P0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2[3OmlEPTB;MD6yOVYzOSEQvF2=NIi1VFNUSU6JRWK=
LXF-289MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\1Z2lEPTB;MD6yOVk5PCEQvF2=NXex[XRJW0GQR1XS
KGNNFjFUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwMk[wPFkh|ryPNFfWN5ZUSU6JRWK=
NCI-H1417NIDJdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTBwMk[1NlQh|ryPMWjTRW5ITVJ?
SF126M4TrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwMkezNFIh|ryPMVfTRW5ITVJ?
SASNXPI[XpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwMkezNFgh|ryPMonKV2FPT0WU
22RV1MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmn5TWM2OD1yLkK3N|c5KM7:TR?=MUDTRW5ITVJ?
GI-1NX3Sc5N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTBwMke0PFch|ryPMYTTRW5ITVJ?
ES3MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXoXY9KSzVyPUCuNlc4PjNizszNNXf1VYg6W0GQR1XS
NB1NF25U2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTETWM2OD1yLkK3PFc3KM7:TR?=Mn;jV2FPT0WU
NCI-H650M1LMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fRbGlEPTB;MD6yPFMxOiEQvF2=NX\rZ4hUW0GQR1XS
IST-MES1M4XYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3KVHdKSzVyPUCuNlg2PTRizszNNHO0epFUSU6JRWK=
UM-UC-3NYjUeWFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjKd5FKSzVyPUCuNlkyPCEQvF2=NWDUfGU5W0GQR1XS
CAL-120NU\0UYpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;BdW5KSzVyPUCuNlk3OzFizszNNIjLWlRUSU6JRWK=
UACC-62MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwM{CyOFEh|ryPNHvWfIpUSU6JRWK=
TE-11Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTBwM{CyOFkh|ryPMm\zV2FPT0WU
MKN1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\uTWM2OD1yLkOwN|Yh|ryPMmD5V2FPT0WU
KS-1M{TYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvQclNKSzVyPUCuN|A2OjZizszNM2K2dHNCVkeHUh?=
GCIYNYDpeJhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTBwM{GwNFIh|ryPNIXHVFVUSU6JRWK=
OVCAR-5M3LWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;nTWM2OD1yLkOxNVA3KM7:TR?=NEHEeJlUSU6JRWK=
U-266M4i5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3nTWM2OD1yLkOxNVQ4KM7:TR?=M2jaOXNCVkeHUh?=
Calu-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHT0UGpKSzVyPUCuN|EzQDlizszNM3XkbnNCVkeHUh?=
SK-LMS-1NYLF[IdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TRVGlEPTB;MD6zNVQzQSEQvF2=NV61R2c5W0GQR1XS
COLO-741M3HKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4roe2lEPTB;MD6zNVYyPCEQvF2=NFvzcZNUSU6JRWK=
RPMI-8226MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrHWFNKSzVyPUCuN|E3PDFizszNMlO4V2FPT0WU
KM12MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHXTWM2OD1yLkOxPFMh|ryPM2SwZnNCVkeHUh?=
NMC-G1NELHWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;YT3ZKSzVyPUCuN|E5PiEQvF2=NFnrWYlUSU6JRWK=
SJRH30NX2yRZhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nRNGlEPTB;MD6zNlA2OiEQvF2=NHnyTJlUSU6JRWK=
COR-L105NV\IUZo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrRTWM2OD1yLkOyNlE5KM7:TR?=NUXTSIFmW0GQR1XS
IM-9NXOz[VZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfuNHRHUUN3ME2wMlM{ODJzIN88US=>NFPMVFJUSU6JRWK=
TE-12MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DPOWlEPTB;MD6zN|MyPyEQvF2=NXTNfnhmW0GQR1XS
KG-1MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfDTWM2OD1yLkOzOFMzKM7:TR?=M3LlenNCVkeHUh?=
U251NVzXVlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTBwM{O0OVYh|ryPNYXxTlVnW0GQR1XS
EFO-27NF7HSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PZcWlEPTB;MD6zN|k2OSEQvF2=MmjsV2FPT0WU
EW-24Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\1TGlEPTB;MD6zN|k5PCEQvF2=NITKZWFUSU6JRWK=
SF295NV30NWF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvwTWM2OD1yLkOzPVk6KM7:TR?=MUfTRW5ITVJ?
MC-IXCMln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHSxZ|lKSzVyPUCuN|Q2KM7:TR?=MkjxV2FPT0WU
NCI-H2405NIfmZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7STWM2OD1yLkO0O|MzKM7:TR?=M2\TUnNCVkeHUh?=
NCI-H2009M{PJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXm1fIp2UUN3ME2wMlM1PzN7IN88US=>NG\uOGdUSU6JRWK=
LB1047-RCCMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fQdGlEPTB;MD6zOVgyPSEQvF2=NWHCeGJTW0GQR1XS
KNS-81-FDMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTBwM{[2Olch|ryPNUDhPHNRW0GQR1XS
HOP-92M1\CXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fncWlEPTB;MD6zOlg{KM7:TR?=MVfTRW5ITVJ?
L-428M3S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLQb|hKSzVyPUCuN|cxOTZizszNNHf3SWVUSU6JRWK=
C3AMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW1WI9KSzVyPUCuN|c{PzlizszNNYGzcnhUW0GQR1XS
NCI-H1792NF2wXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTYR5RjUUN3ME2wMlM4PjV3IN88US=>MmLIV2FPT0WU
HuH-7NFnucIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mln3TWM2OD1yLkO3PVEh|ryPMm\rV2FPT0WU
AGSNEK2UWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\GbmlEPTB;MD6zPFY{QCEQvF2=Mki4V2FPT0WU
HT-1197NHrqUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojiTWM2OD1yLkO5OFYh|ryPMmXIV2FPT0WU
CGTH-W-1NEPG[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIiwemJKSzVyPUCuN|k6OTNizszNNUH0RoRlW0GQR1XS
KNS-42NXXrdo9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTBwNECwOFUh|ryPMUnTRW5ITVJ?
HuO-3N1M2O2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LtVGlEPTB;MD60NFA2PSEQvF2=NViyO3prW0GQR1XS
VMRC-RCZNU\jb4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:3T|VKUUN3ME2wMlQxOzB|IN88US=>NHX2N|BUSU6JRWK=
SW954MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vDemlEPTB;MD60NFM{PSEQvF2=NX7P[2tIW0GQR1XS
MES-SAM3q1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDDTWM2OD1yLkSwOVA2KM7:TR?=NVnRdZZwW0GQR1XS
Ca-SkiNWDTOWhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7s[mh4UUN3ME2wMlQxPTJ2IN88US=>NGThdFJUSU6JRWK=
SW13MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPnOWo5UUN3ME2wMlQxPjJ4IN88US=>NEnZWGNUSU6JRWK=
NCI-H1437MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Hxe2lEPTB;MD60NFgxPSEQvF2=NFrLTXVUSU6JRWK=
U-118-MGNEfoVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwNEC5NFQh|ryPMYTTRW5ITVJ?
NCI-H1734MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDqTGlKSzVyPUCuOFIxOTNizszNMULTRW5ITVJ?
HDLM-2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\qTWM2OD1yLkSyNFM{KM7:TR?=MkLaV2FPT0WU
AU565NHzMfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTBwNEK0Olgh|ryPNV\DdncxW0GQR1XS
FADUMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofETWM2OD1yLkSyOlQ6KM7:TR?=NHvYXm9USU6JRWK=
OS-RC-2NWfzUZdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXtTWM2OD1yLkSzNFg{KM7:TR?=NIXROoZUSU6JRWK=
CAMA-1M3rQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwNEO2NlYh|ryPNIPsUYFUSU6JRWK=
MONO-MAC-6NUD5UI9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TKcWlEPTB;MD60N|g1QSEQvF2=MXfTRW5ITVJ?
LB831-BLCMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTBwNESzO|Eh|ryPMlfMV2FPT0WU
SW982M4rhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPFTWM2OD1yLkS0OVI5KM7:TR?=NFXtcZZUSU6JRWK=
SCC-3M3\hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIKxVWhKSzVyPUCuOFQ2PzlizszNNUnVV4hXW0GQR1XS
C32MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1yweWlEPTB;MD60OVIzQSEQvF2=NXjGcVA2W0GQR1XS
BFTC-909NEfie5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIn6cGxKSzVyPUCuOFUzQTlizszNNFTV[XJUSU6JRWK=
MEG-01Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDrTWM2OD1yLkS1N|c{KM7:TR?=MnG5V2FPT0WU
M14M3L2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYe4b3VrUUN3ME2wMlQ2QTd7IN88US=>M4DuR3NCVkeHUh?=
MPP-89NHPwdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[xTWM2OD1yLkS2NlU3KM7:TR?=MmnnV2FPT0WU
HCC1937MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTBwNE[zPFQh|ryPNFLQV2NUSU6JRWK=
SW837MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwNE[3NlIh|ryPMkLNV2FPT0WU
DU-145NU\zWVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTBwNE[3Nlkh|ryPMXTTRW5ITVJ?
LB996-RCCNEnQdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnM[IlKSzVyPUCuOFcxPTRizszNMlzCV2FPT0WU
C8166M3fY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmOwTWM2OD1yLkS3OEDPxE1?NXrCWllPW0GQR1XS
MOLT-4Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjSdHhJUUN3ME2wMlQ4PzN2IN88US=>M2HpSnNCVkeHUh?=
DMS-53MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTBwNEe4NFkh|ryPNEHYNmNUSU6JRWK=
TE-5MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkCwTWM2OD1yLkS4N|A2KM7:TR?=M3v3ZnNCVkeHUh?=
KYSE-520NWT2cYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGez[opKSzVyPUCuOFg{PDNizszNMn3xV2FPT0WU
Detroit562NXzVZ5VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTlRWRKSzVyPUCuOFg5PiEQvF2=M2\2RXNCVkeHUh?=
SIMANIO1doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;2UpVsUUN3ME2wMlQ6PDF5IN88US=>M3HjcXNCVkeHUh?=
NCI-H1651MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTBwNEm2O{DPxE1?MUTTRW5ITVJ?
HCC1599MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XQSGlEPTB;MD60PVk2PSEQvF2=NELMNnFUSU6JRWK=
ABC-1M1HNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITNfYpKSzVyPUCuOVA1QTZizszNM4rh[HNCVkeHUh?=
CAL-33NYOxcFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTBwNUC4OFQh|ryPNUjIRYYyW0GQR1XS
OPM-2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnuyTWM2OD1yLkWwPVM4KM7:TR?=MVPTRW5ITVJ?
RPMI-7951MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwNUC5OVch|ryPMl7nV2FPT0WU
HT-1080NX65XoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7vTWM2OD1yLkWxNVE6KM7:TR?=NWPTS2x7W0GQR1XS
LC4-1M{HDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfrbZRXUUN3ME2wMlUyPDB|IN88US=>M1OzZ3NCVkeHUh?=
OVCAR-3NFjjPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnhZpVKSzVyPUCuOVE2PyEQvF2=MULTRW5ITVJ?
CAPAN-1MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fMSWlEPTB;MD61NlI5QCEQvF2=NYfnOnpOW0GQR1XS
SK-OV-3MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzFTWM2OD1yLkWyOFM1KM7:TR?=MX;TRW5ITVJ?
HuP-T3Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwNUK4Nlch|ryPM1zXZnNCVkeHUh?=
NCI-H838MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPhRo1lUUN3ME2wMlUzQDR7IN88US=>M3LCd3NCVkeHUh?=
K5NF\mWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGi2TWdKSzVyPUCuOVMzODFizszNM4TI[nNCVkeHUh?=
CAL-72M365fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjUU4VKSzVyPUCuOVM{QDdizszNNXjKZo56W0GQR1XS
NH-12Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTBwNUO5OVkh|ryPNWXP[ZFCW0GQR1XS
SNB75M4SxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwNUW3N{DPxE1?MWfTRW5ITVJ?
BPH-1MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PzS2lEPTB;MD61OlM1PCEQvF2=MVPTRW5ITVJ?
NOMO-1M3PEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HKVGlEPTB;MD61OlM4OiEQvF2=NILu[VNUSU6JRWK=
G-402MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jpUWlEPTB;MD61OlQ6QSEQvF2=M{DYenNCVkeHUh?=
NCI-H2052MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\ZZWlEPTB;MD61Olc1OSEQvF2=M4W4dnNCVkeHUh?=
RCM-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{noRmlEPTB;MD61O|E3PiEQvF2=MYLTRW5ITVJ?
COR-L279NETINZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPpZ41KSzVyPUCuOVcyQDVizszNMkTYV2FPT0WU
A253M33IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwNUe1NlUh|ryPMlT5V2FPT0WU
SK-MM-2M1XD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV2wSndjUUN3ME2wMlU4Pjd7IN88US=>NW\PcG16W0GQR1XS
NCI-H1703NEPQcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTBwNUm0Nlch|ryPM36wTnNCVkeHUh?=
UACC-257NVfOS|R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDaTWM2OD1yLkW5OFg4KM7:TR?=M3fqUXNCVkeHUh?=
KALS-1MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTBwNkCwNVEh|ryPNV7rclQ1W0GQR1XS
ES5MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPSPFBKSzVyPUCuOlA1QCEQvF2=MWjTRW5ITVJ?
MHH-CALL-2NX71WWx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwNkC4PFgh|ryPMoPqV2FPT0WU
ChaGo-K-1M362c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTBwNkGyNlkh|ryPMWTTRW5ITVJ?
TGBC1TKBNEnxcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPmWHI2UUN3ME2wMlYyQThizszNMlX4V2FPT0WU
KU-19-19MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XOemlEPTB;MD62OFU5PiEQvF2=M1S3RnNCVkeHUh?=
COLO-684NH7zOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vtWWlEPTB;MD62OVYyOSEQvF2=M4PuOnNCVkeHUh?=
LS-1034NGXNUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jsVWlEPTB;MD62OVgyQSEQvF2=NHrFOYxUSU6JRWK=
RT-112NYXod2VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4X6d2lEPTB;MD62OlU5PyEQvF2=MlHJV2FPT0WU
Capan-2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\QVohKSzVyPUCuOlY3OjJizszNNX;PWpZMW0GQR1XS
HSC-4M1nydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrFTWM2OD1yLk[2Olk5KM7:TR?=MXPTRW5ITVJ?
COLO-824NHPWZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTBwNke4NlMh|ryPM3X1fXNCVkeHUh?=
NCI-H2170M3;MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnyzTWM2OD1yLk[4NlU5KM7:TR?=MXvTRW5ITVJ?
GDM-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP2TWM2OD1yLk[4OFk1KM7:TR?=MXTTRW5ITVJ?
KP-4NFTEfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzZc|Q6UUN3ME2wMlY6PTd|IN88US=>M2fhUXNCVkeHUh?=
VA-ES-BJM3LEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfwcW1KSzVyPUCuOlk6QDZizszNNU\jRXlwW0GQR1XS
KM-H2M1\6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXH2T4wxUUN3ME2wMlcxODlzIN88US=>M{TXSXNCVkeHUh?=
HHMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwN{C2OlIh|ryPM1XuSHNCVkeHUh?=
DK-MGMo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTBwN{GwNVYh|ryPNHfTU4ZUSU6JRWK=
VM-CUB-1NFzWe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTBwN{GyOVkh|ryPMmLVV2FPT0WU
COLO-829NUTHW4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3u2U2lEPTB;MD63NVk5PSEQvF2=MYLTRW5ITVJ?
OMC-1M2nDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTmTWM2OD1yLkeyNVA1KM7:TR?=MmKxV2FPT0WU
NB12M13HWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TZbGlEPTB;MD63NlUxPCEQvF2=Mm\VV2FPT0WU
NCI-H28M3PVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDWV|hEUUN3ME2wMlc1ODh|IN88US=>NUSxNWlGW0GQR1XS
A673MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXaVnloUUN3ME2wMlc2OTd5IN88US=>Mnf3V2FPT0WU
LB2241-RCCMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTBwN{[wPFch|ryPNYjweZFqW0GQR1XS
CCRF-CEMM2\NWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwN{ewOVIh|ryPMoPnV2FPT0WU
NCI-H510ANVizN5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTBwN{exPFYh|ryPM{f5Z3NCVkeHUh?=
SW48MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwN{ezN|Mh|ryPM{LzR3NCVkeHUh?=
NCI-H2081NGPxZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTBwN{ixOFch|ryPMWfTRW5ITVJ?
RMG-INHHtRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPiSlQ5UUN3ME2wMlc5OjF{IN88US=>MWrTRW5ITVJ?
LU-99AM4rIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTBwN{i0NVMh|ryPM2[zN3NCVkeHUh?=
KP-N-YSNXPpZohlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTBwN{i5NlEh|ryPNELpfVVUSU6JRWK=
MDA-MB-231M{fjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2m0U2lEPTB;MD64NFE{OSEQvF2=NFTPWWVUSU6JRWK=
U031Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrLfllKSzVyPUCuPFE1OjNizszNM{Hnb3NCVkeHUh?=
EVSA-TMoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfyVI5KSzVyPUCuPFE3PzJizszNNFL4V3BUSU6JRWK=
MDA-MB-157M2L0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTBwOEKyO|Eh|ryPM3q4ZXNCVkeHUh?=
EHEBM4X4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG[4XolKSzVyPUCuPFIzPzZizszNMXLTRW5ITVJ?
KINGS-1M{DTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwOEK1OVUh|ryPMYXTRW5ITVJ?
23132-87NUDVOIhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\NWopKSzVyPUCuPFI5PDNizszNNIi2UIpUSU6JRWK=
EFO-21NF\TN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDMR2JKSzVyPUCuPFQxQDlizszNNYfKRmV2W0GQR1XS
DOKMn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHzTWM2OD1yLki0PEDPxE1?NVrJbppUW0GQR1XS
NCI-H2171MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPkbItKSzVyPUCuPFQ6PiEQvF2=MVPTRW5ITVJ?
NCI-SNU-5NWTxSmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mom0TWM2OD1yLki1OVch|ryPMmT3V2FPT0WU
SK-N-DZMmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLBNnpnUUN3ME2wMlg2QTR|IN88US=>MmL1V2FPT0WU
SNU-C2BNYLCUVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGi2UFNKSzVyPUCuPFY5ODFizszNMWnTRW5ITVJ?
CP66-MELNF25RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2e5NmlEPTB;MD64O|EyKM7:TR?=NV3QXWIyW0GQR1XS
SN12CM1noTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDTWI5KSzVyPUCuPFg3OzdizszNNULQSJJLW0GQR1XS
A172Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\hTWM2OD1yLki4Olk5KM7:TR?=MYXTRW5ITVJ?
NCI-H2347NUWzfG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWP4cY5qUUN3ME2wMlg5PzV|IN88US=>MmnuV2FPT0WU
NCI-H2228M3jUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLJTWM2OD1yLki5N|M6KM7:TR?=NVfhSYJDW0GQR1XS
SNU-387MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13q[WlEPTB;MD65NFI3PCEQvF2=NEDKOGZUSU6JRWK=
SK-MEL-24M1Ho[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLuTWM2OD1yLkmxN|Q1KM7:TR?=M{XGe3NCVkeHUh?=
MDA-MB-468MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfDTWM2OD1yLkmxO|Mh|ryPNWnpfWJuW0GQR1XS
NCI-H1694M1\mbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nxT2lEPTB;MD65NVg4PiEQvF2=M3zaT3NCVkeHUh?=
CCF-STTG1NW[4VHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHLTWM2OD1yLkmyOlM4KM7:TR?=NIPC[odUSU6JRWK=
K052NGHCWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{L6emlEPTB;MD65OFA1PyEQvF2=MYHTRW5ITVJ?
NCI-H446NX\rfWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPPSVZKSzVyPUCuPVUxOSEQvF2=M1fK[nNCVkeHUh?=
MFE-280Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M322UmlEPTB;MD65OlI6OSEQvF2=NYOyOWk2W0GQR1XS
KU812NX25UnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlu0TWM2OD1yLkm5N|g6KM7:TR?=M162OnNCVkeHUh?=
MDA-MB-361MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYO4WYtMUUN3ME2wMlk6Pzd5IN88US=>MYrTRW5ITVJ?
RajiMnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\h[HRKSzVyPUGuNFIzPjdizszNMnTTV2FPT0WU
TE-6M1y5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXW3Z5FNUUN3ME2xMlA{PTZ4IN88US=>MnHoV2FPT0WU
CAL-148MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTFwMES0OFMh|ryPM2\ueXNCVkeHUh?=
NCI-H1963MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M333Z2lEPTB;MT6wOFU2OyEQvF2=MUPTRW5ITVJ?
SK-N-ASNHP6fYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3FeIJEUUN3ME2xMlA1Pjh3IN88US=>MojsV2FPT0WU
RERF-LC-MSMn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHYb5plUUN3ME2xMlA3OzR7IN88US=>NHvWcndUSU6JRWK=
BENM2nlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2OxTWlEPTB;MT6wO|E{PyEQvF2=NWm5cmltW0GQR1XS
CAS-1NVvKXoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjETG1RUUN3ME2xMlA6OTJ|IN88US=>NWHIUXpsW0GQR1XS
SW780MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFwMEmxPFEh|ryPNXf2cYV5W0GQR1XS
LU-65MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTFwMEm0NUDPxE1?NECwfYtUSU6JRWK=
D-283MEDNFTxdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nqO2lEPTB;MT6xNlI4OiEQvF2=MnnTV2FPT0WU
HCC2157Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHJTWM2OD1zLkGzOlQzKM7:TR?=NGnMVXZUSU6JRWK=
RCC10RGBNXjZZVljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTFwMUSwNFYh|ryPNH60fWhUSU6JRWK=
PLC-PRF-5NED2SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTFwMUWyNlkh|ryPM4nMfHNCVkeHUh?=
H4MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXe4N5UyUUN3ME2xMlE2PDN7IN88US=>Mor0V2FPT0WU
TURM4HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUmwfYEzUUN3ME2xMlE2PzV{IN88US=>NYjPVXU4W0GQR1XS
NCI-H2141MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3rZ3JKSzVyPUGuNVg6PDZizszNM1;uT3NCVkeHUh?=
PFSK-1NVL1W2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUKxPIVSUUN3ME2xMlIxPTN{IN88US=>M123THNCVkeHUh?=
SK-MEL-28NFPqVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXhTVRKSzVyPUGuNlMzOjFizszNMlG3V2FPT0WU
SCC-9NVnOdG1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLsdGVFUUN3ME2xMlI{PjZ3IN88US=>MWLTRW5ITVJ?
T47DNUXPSnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{SyW2lEPTB;MT6yN|Y6PiEQvF2=MV;TRW5ITVJ?
TCCSUPM1zyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFwMkWwNlkh|ryPM3fqfXNCVkeHUh?=
SU-DHL-1Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTFwMkWxNVgh|ryPMY\TRW5ITVJ?
HL-60MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjDfXVKSzVyPUGuNlU2QDhizszNM4W3NHNCVkeHUh?=
NCI-H1436MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;oTWM2OD1zLkK2NVQ6KM7:TR?=NFzKfYFUSU6JRWK=
DMS-114NH3Yb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mly5TWM2OD1zLkK2OlMzKM7:TR?=NVj6VI93W0GQR1XS
BOKUMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnHS2dTUUN3ME2xMlI5ODl3IN88US=>MYnTRW5ITVJ?
MS-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkD6TWM2OD1zLkK5NFY6KM7:TR?=M{n4ZnNCVkeHUh?=
NCI-H661Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjKOJdKSzVyPUGuN|A1PzhizszNMkLUV2FPT0WU
HT-3M{DmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTFwM{C1Nlkh|ryPM1PCVXNCVkeHUh?=
CAL-54M{TST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPxTWM2OD1zLkOwO|I2KM7:TR?=Mm\GV2FPT0WU
SW1463MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTFwM{G4O|Ih|ryPNFLSOnNUSU6JRWK=
COLO-668MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1GwcWlEPTB;MT6zN|A2PiEQvF2=MUXTRW5ITVJ?
PANC-08-13MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFwM{O4NFMh|ryPM37xR3NCVkeHUh?=
BB49-HNCNYDPNHRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTFwM{SwNUDPxE1?M{\W[XNCVkeHUh?=
M059JMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK4clZKSzVyPUGuN|U5OzJizszNMWXTRW5ITVJ?
NCCITNYPUZ3NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTFwM{e5PFgh|ryPNUD1V3pwW0GQR1XS
LN-405NFraNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTFwM{myOlQh|ryPMVPTRW5ITVJ?
UMC-11Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFP6VJVKSzVyPUGuN|k6QTZizszNNX7lPJFzW0GQR1XS
NB5NF\rd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTFwNEGyNlch|ryPNVLCPXVMW0GQR1XS
TE-441-TNVLteIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjqc3p2UUN3ME2xMlQzQDF5IN88US=>M3H4UXNCVkeHUh?=
ME-180M{KwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmr0TWM2OD1zLkS0N|kzKM7:TR?=NHiwRo9USU6JRWK=
HCC70NVjz[oNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLC[I9lUUN3ME2xMlQ3ODl4IN88US=>NHvofGNUSU6JRWK=
no-10M2DVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXy4bIozUUN3ME2xMlQ3OThzIN88US=>NHiyO|BUSU6JRWK=
JEG-3NVXKWnVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33yU2lEPTB;MT61NFE{OiEQvF2=MVHTRW5ITVJ?
no-11Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHP2bZhKSzVyPUGuOVA5QDJizszNMVnTRW5ITVJ?
CHP-126M3THc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfLbok1UUN3ME2xMlU3PjlzIN88US=>M2LhVnNCVkeHUh?=
EGI-1MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfOTWM2OD1zLkW4NFI2KM7:TR?=M4m2[HNCVkeHUh?=
D-392MGNXz5UWl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[5SZJXUUN3ME2xMlU6PjNizszNMoGwV2FPT0WU
RT4MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnsXYdlUUN3ME2xMlU6PjN5IN88US=>MknMV2FPT0WU
A204NV60boozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFwNUm4NFEh|ryPM4HVOHNCVkeHUh?=
NCI-H1304NWjXZ5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHudFZKSzVyPUGuOlM2QTFizszNMkLIV2FPT0WU
BeckerNELhTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HlWWlEPTB;MT62OFI1OSEQvF2=MkTuV2FPT0WU
OE19M1HJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HHRmlEPTB;MT62OVUyQCEQvF2=M1jxVnNCVkeHUh?=
EKVXMoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfRTWM2OD1zLk[1OlE5KM7:TR?=NWjYT3FmW0GQR1XS
KLENYLZdFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7yRZlKSzVyPUGuOlU4OTRizszNMlyxV2FPT0WU
K-562M1jZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWGxUpc4UUN3ME2xMlY4ODN5IN88US=>NFi1[VlUSU6JRWK=
MDA-MB-175-VIIMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPhTWM2OD1zLk[4PVk4KM7:TR?=M1zLO3NCVkeHUh?=
NCI-H716NVjPN3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrnTWM2OD1zLk[5N|A1KM7:TR?=MlTlV2FPT0WU
Caov-3NHq4S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\neG1bUUN3ME2xMlY6PDF|IN88US=>MkH2V2FPT0WU
HCC1187NYXsbHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XyOGlEPTB;MT63NFU1PSEQvF2=NELZXmhUSU6JRWK=
CAKI-1NI\PSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTobYZKSzVyPUGuO|IzQTJizszNMl3TV2FPT0WU
MOLT-16NU\XcWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jvSmlEPTB;MT63N|MxPyEQvF2=NIHsO4ZUSU6JRWK=
PC-3MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTFwN{WwPEDPxE1?MU\TRW5ITVJ?
DV-90M{jpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXHTWM2OD1zLke1OVg2KM7:TR?=NHHGVJpUSU6JRWK=
RXF393MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTFwN{eyPVQh|ryPMn;pV2FPT0WU
SK-NEP-1NW[xdWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzYWlRKSzVyPUGuPFI{OzlizszNNWDzNnV1W0GQR1XS
HCC1419NYDhcZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1OzO2lEPTB;MT64NlY6OiEQvF2=MnTXV2FPT0WU
BV-173NXrPW|lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLyTWM2OD1zLkiyPVk2KM7:TR?=M2[3dXNCVkeHUh?=
MKN7M4TQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDHfXlXUUN3ME2xMlg6OjJizszNNHXKWmpUSU6JRWK=
LAN-6MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDnfYdLUUN3ME2xMlg6PTV|IN88US=>MonEV2FPT0WU
Mo-TM3jDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjVTWM2OD1zLkmwNFM6KM7:TR?=NFLiWZBUSU6JRWK=
HCC1395MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jIc2lEPTB;MT65Nlg3OyEQvF2=MV;TRW5ITVJ?
HC-1NGnROWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTFwOUO0O{DPxE1?NFzhepZUSU6JRWK=
HPAF-IIMoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrlU5RKSzVyPUGuPVQ1OThizszNNV3pdZU1W0GQR1XS
CPC-NMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn61TWM2OD1zLkm4NFAzKM7:TR?=MV\TRW5ITVJ?
MKN45MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHXTWM2OD1zLkm5NVE6KM7:TR?=NH\wOJVUSU6JRWK=
NCI-H1693NW\pU5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfMTWM2OD1{LkCwOFM{KM7:TR?=MVLTRW5ITVJ?
SHP-77MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjpTWM2OD1{LkCwOVM{KM7:TR?=MYPTRW5ITVJ?
NCI-H1522M3fVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPZTWM2OD1{LkCxO|I1KM7:TR?=M1jBVXNCVkeHUh?=
SW1573NYXRZm9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGX0SVNKSzVyPUKuNFIzKM7:TR?=Mkj3V2FPT0WU
DBTRG-05MGNI\Oc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zVcmlEPTB;Mj6wOlA5PyEQvF2=NYjOSFh7W0GQR1XS
SCC-4MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnMWGVzUUN3ME2yMlE1OzFizszNM2LYPHNCVkeHUh?=
DMS-153NYDrV49IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPrO2tKSzVyPUKuNVY3PjhizszNNI\aZXpUSU6JRWK=
MDA-MB-415MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojoTWM2OD1{LkG3OVIh|ryPM17Rb3NCVkeHUh?=
NCI-H2126MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXmTWM2OD1{LkKyPFg5KM7:TR?=NXS3W2U3W0GQR1XS
MDA-MB-453NYHvSHFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJwMkOzNkDPxE1?NWTvNFF{W0GQR1XS
U-87-MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHL3dHFKSzVyPUKuNlg2QTJizszNNXr5c4p{W0GQR1XS
LNCaP-Clone-FGCM1u5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfjfGxKSzVyPUKuN|AyODJizszNMWLTRW5ITVJ?
NCI-H1581MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFKxSYZKSzVyPUKuN|IyODVizszNNHH2dFVUSU6JRWK=
BC-3NEXCeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnS5TWM2OD1{LkO2OVA6KM7:TR?=NFrpd49USU6JRWK=
HCC38NUDkO2JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXz6UnZYUUN3ME2yMlM5PDR5IN88US=>NEXYeoxUSU6JRWK=
HCC2218Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PJZmlEPTB;Mj60NFgxQSEQvF2=MmfYV2FPT0WU
RO82-W-1NVywSGt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DUemlEPTB;Mj60NVI2KM7:TR?=MXHTRW5ITVJ?
C2BBe1NWfueVFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXWW4o4UUN3ME2yMlQyPTd6IN88US=>M4rOd3NCVkeHUh?=
LAMA-84NX7Bd285T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfwNYZKSzVyPUKuOVc{PjhizszNNXHNUlNzW0GQR1XS
GMS-10MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle2TWM2OD1{LkW3OlEyKM7:TR?=NGnDXY1USU6JRWK=
GCTNV;CVXdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnkVWVKSzVyPUKuOVg3QTRizszNM1rJZ3NCVkeHUh?=
SK-CO-1MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkj5TWM2OD1{Lk[xOlYh|ryPMWnTRW5ITVJ?
NCI-H526Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF2xZWRKSzVyPUKuOlM1PSEQvF2=M3ztfHNCVkeHUh?=
SW1088M4nweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\YfphKSzVyPUKuO|c5OzlizszNNH;3T4NUSU6JRWK=
HT55M2fCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3j3e2lEPTB;Mj63PFY6PSEQvF2=MV7TRW5ITVJ?
NB10NFqxZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTJwOEG3OFgh|ryPMmnBV2FPT0WU
UACC-893NFj6PGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1v4O2lEPTB;Mj64OVc1QSEQvF2=Mn7VV2FPT0WU
NCI-H1618M2PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXmTWM2OD1{Lki4NVU{KM7:TR?=MWjTRW5ITVJ?
NCI-H1092MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTNwMEe4NVIh|ryPNV7TUlU1W0GQR1XS
SBC-1MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHTTWM2OD1|LkC4OVU{KM7:TR?=MnXaV2FPT0WU
NCI-H1623NVjoW3hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrqNplFUUN3ME2zMlA6OzRizszNMlixV2FPT0WU
SiHaNH3JfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PrWGlEPTB;Mz6xNVk4PyEQvF2=NX7rbZlPW0GQR1XS
D-263MGMnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nRdGlEPTB;Mz6xOFc5QCEQvF2=NWGyNW1VW0GQR1XS
NCI-H1573M2fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLJZ4xjUUN3ME2zMlE6PjRzIN88US=>Mnq2V2FPT0WU
NCI-H82M4Lx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTNwM{S0N|kh|ryPMYfTRW5ITVJ?
NCI-H2196NELQV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTYTWM2OD1|LkO1NFA5KM7:TR?=Mn3DV2FPT0WU
MFM-223NXz2dlRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTZTWM2OD1|LkO3N|UyKM7:TR?=MlHaV2FPT0WU
COLO-678M3PIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O4TWlEPTB;Mz6zPFE5PiEQvF2=NWC3XZB7W0GQR1XS
EW-3MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXifVRKSzVyPUOuOFA6PSEQvF2=NVvVO2NlW0GQR1XS
MHH-NB-11MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLTTWM2OD1|LkS0NFY6KM7:TR?=NV;SbW1WW0GQR1XS
EM-2Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLsTWM2OD1|Lk[zPVgh|ryPNHXpTHVUSU6JRWK=
FTC-133NHzYZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkeyTWM2OD1|Lk[1OFU5KM7:TR?=NEXkb5VUSU6JRWK=
NCI-H209NXT2PVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnEfnFMUUN3ME2zMlY4PjV|IN88US=>MnvNV2FPT0WU
TGBC24TKBMoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2D4cGlEPTB;Mz62PFM2PSEQvF2=MYHTRW5ITVJ?
LC-1FMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULRZ2pmUUN3ME2zMlcyPzZ2IN88US=>NIDWO3lUSU6JRWK=
C-4-IIM13ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTNwN{W2OFMh|ryPMVzTRW5ITVJ?
NCI-H1650M4flRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DpNmlEPTB;Mz63PFQ2PSEQvF2=MnnkV2FPT0WU
JVM-2M{TldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M36yVWlEPTB;Mz65N|Y{QSEQvF2=M4jxNXNCVkeHUh?=
CaR-1NXfvXZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHURXpKSzVyPUOuPVc3OTdizszNM13ZdnNCVkeHUh?=
MDA-MB-134-VIMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFS4[I1KSzVyPUSuNFI6PTJizszNM3rORnNCVkeHUh?=
NCI-H719M3fpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTRwMUWzPFgh|ryPMnfHV2FPT0WU
GOTONETzdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTRwMkm3NFUh|ryPNYLJ[mVqW0GQR1XS
NCI-N87NEnQfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHSTWM2OD12LkO4PFIyKM7:TR?=M4D5dnNCVkeHUh?=
NB6NEfnUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3Mb|B6UUN3ME20MlQzPTB7IN88US=>MX7TRW5ITVJ?
DSH1NILlZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoS5TWM2OD12LkS3NVE3KM7:TR?=NIjz[VdUSU6JRWK=
BT-20M1fH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnlTWM2OD12LkS5NFAzKM7:TR?=NH3ofpBUSU6JRWK=
NCI-H1882M3;WV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrQbXFKSzVyPUSuOVA2PyEQvF2=MW\TRW5ITVJ?
WM-115MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnr[2FXUUN3ME20MlUxQDhzIN88US=>M2TJbHNCVkeHUh?=
SKG-IIIaNIjzVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXCVVlzUUN3ME20MlY4PzdizszNMYXTRW5ITVJ?
NCI-H69M{fVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTqOnRCUUN3ME20MlcxOjd3IN88US=>NFTPenJUSU6JRWK=
MSTO-211HNVLNbmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXvTGlKSzVyPUSuPFM2PjVizszNNXfrS2czW0GQR1XS
MewoM4DoZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PvVWlEPTB;ND65OlMyOyEQvF2=NUW2cJRjW0GQR1XS
GI-ME-NM4DaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3P3e2lEPTB;NT6wNFUxQSEQvF2=MVXTRW5ITVJ?
T98GMmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoS1TWM2OD13LkC2OVA5KM7:TR?=M4PyWHNCVkeHUh?=
ECC4NX[wXHB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTQTWM2OD13LkC5N|czKM7:TR?=MnfmV2FPT0WU
EW-11MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX6dI5wUUN3ME21MlE5ODl7IN88US=>NWnEcWllW0GQR1XS
COLO-800MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvTeVQ6UUN3ME21MlE6OzR7IN88US=>MmKwV2FPT0WU
NCI-H1755M1:4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rBTWlEPTB;NT6yN|AzPyEQvF2=NVnmUWhNW0GQR1XS
KMS-12-PEM3OxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTVwM{WwPFUh|ryPMVvTRW5ITVJ?
HCC1954M{jWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLhWJVsUUN3ME21Mlg2QTdzIN88US=>Mo\4V2FPT0WU
NCI-H187M1;sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjoe3NKSzVyPUWuPVI6QDlizszNNV3BdndvW0GQR1XS
LU-165Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTVwOUmwNFIh|ryPNWnFPZNyW0GQR1XS
YAPCMljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLzWWJKSzVyPUWuPVkxPjhizszNMXrTRW5ITVJ?
LU-139MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHYTWM2OD14LkC4N|Y5KM7:TR?=M3rTcnNCVkeHUh?=
D-502MGMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nIZWlEPTB;Nj6zNlA1PyEQvF2=NX;HPHltW0GQR1XS
IST-SL1NXO1WWRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmP2TWM2OD14LkWzPVQ5KM7:TR?=MX7TRW5ITVJ?
DG-75M2Gx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;rWHJKSzVyPU[uPFg4QDZizszNM2rWdXNCVkeHUh?=
NCI-H1155MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jp[mlEPTB;Nj65OVU5OSEQvF2=MkTMV2FPT0WU
EFE-184MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnK1TWM2OD15LkOxOlk2KM7:TR?=MlXGV2FPT0WU
AsPC-1NFLvZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;kWGlEPTB;Nz60PFgxPyEQvF2=MlPzV2FPT0WU
SW948MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnz6TWM2OD15LkW4N|k2KM7:TR?=NYXJWo5DW0GQR1XS
NCI-H524Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzo[IdqUUN3ME25MlU5PjJ6IN88US=>NXjPd21VW0GQR1XS
KOSC-2NULye5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTlwNkK4N|Qh|ryPMknSV2FPT0WU
T-24NVX4RoFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7De494UUN3ME25Mlk1PDF3IN88US=>M4XsUXNCVkeHUh?=
NCI-H748MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1L4XGlEPTB;MUCuOlM6PyEQvF2=MXHTRW5ITVJ?
NCI-H23MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn60TWM2OD1zMD62OFQzKM7:TR?=NIezWmRUSU6JRWK=
UACC-812NXXJW|E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\ENWlEPTB;MUGuO|E4KM7:TR?=NGj4V2tUSU6JRWK=
SCLC-21HMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vyd2lEPTB;MUKuNVU2OSEQvF2=MY\TRW5ITVJ?
NCI-SNU-16MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHnZYdKSzVyPUGzMlEzPThizszNNYfRdHd1W0GQR1XS
HD-MY-ZNVXuXZdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\ITWM2OD1zND62N|Y{KM7:TR?=M4K5d3NCVkeHUh?=
SK-N-FIMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzWUpVKSzVyPUG0Mlg6OTJizszNNIfGfYZUSU6JRWK=
LB647-SCLCNXL0WoRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTF3LkexPVUh|ryPMVzTRW5ITVJ?
NCI-H345M1K0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jLdmlEPTB;MUeuN|Q{KM7:TR?=NGnJRW5USU6JRWK=
NCI-H1563NU\lenJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTF6Lke2NFEh|ryPNV;hWIlpW0GQR1XS
RLMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjIbFFKSzVyPUKxMlI3PTZizszNMVTTRW5ITVJ?
KY821Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\Kc3hKSzVyPUKyMlA2PTNizszNM1ziV3NCVkeHUh?=
JVM-3MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHOc2tKSzVyPUK1MlA1OTNizszNMorFV2FPT0WU
NCI-H1793NHXtXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjBOnlKSzVyPUK4MlU1QTlizszNNYf0fG9uW0GQR1XS
LU-134-AMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TDRmlEPTB;M{CuNlA{PyEQvF2=NVnXdpV{W0GQR1XS
NCI-H1395NUfs[2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrMcmhKSzVyPUOyMlI1OzFizszNMl7KV2FPT0WU
NCI-H1993NUGwPJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzzTWM2OD1|Mj64NlE5KM7:TR?=NWixO5VQW0GQR1XS
P31-FUJNGi1VndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfQTWM2OD1|Mz60PFk6KM7:TR?=NHKzXZpUSU6JRWK=
LS-513MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHixemZKSzVyPUO1Mlg5PzlizszNMkPBV2FPT0WU
SK-MEL-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zs[GlEPTB;NECuN|Q6QSEQvF2=NFrXUIFUSU6JRWK=
SW684NV;yZpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37DemlEPTB;NEOuPVY3OSEQvF2=NFPiVFhUSU6JRWK=
COR-L88MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTR2LkC2OlUh|ryPMoWzV2FPT0WU
NCI-H889NEjRbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIX1N2hKSzVyPUS1MlAxQDdizszNNGjJWYJUSU6JRWK=
TALL-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHhTWM2OD12Nj6xNVk6KM7:TR?=MYTTRW5ITVJ?
KARPAS-299Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jJ[GlEPTB;NEeuNVk6OyEQvF2=M{fD[3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Protocol(Only for Reference)

Kinase Assay: [1]

Bcl-2 Binding affinity calculation A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.

Cell Assay: [2]

Cell lines Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
Concentrations ~10 μM
Incubation Time 48-72 hours
Method Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.

Animal Study: [1]

Animal Models Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
Formulation Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
Dosages 0.0313, 0.25, 0.5 and 2 mg/kg
Administration Administered intravenously (tail vein) once a day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.

[2] Trudel S, et al. Blood, 2009, 113(2), 299-305.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymp  ...more Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|  ...more Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2

view more

Chemical Information

Download Obatoclax Mesylate (GX15-070) SDF
Molecular Weight (MW) 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 83 mg/mL (200.73 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (Z)-2-(5-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-4-methoxy-5H-pyrrol-2-yl)-1H-indole mesylate

Customer Product Validation(9)


Click to enlarge
Rating
Source Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Mice
Concentrations 3 mg/kg
Incubation Time 3 weeks
Results Tumors from 3 mice in each group were analyzed with H&E and immunohistochemical staining. Interestingly, H&E staining revealed substantially increased necrosis in the tumors for GX15-070 treated groups compared to the vehicle control group, especially for the combination (AZD2281 and GX15-070) group.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Electron microscopic morphology
Cell Lines T1682 cells
Concentrations 100, 1000 nM
Incubation Time 1, 6, 48 h
Results Gx15-070 treatment of TET cells leads to both growth inhibition and cell death. Gx15-070 induces autophagy-dependent necroptosis in acute lymphoblastic leukemia cells, it's performed electron microscopy (EM) in TET cells, which demonstrated changes in mitochondrial structure as early signs of autophagy after 1 h Gx15-070 treatment. After 6 h treatment, cytoplasmic vacuolization and mitochondrial swelling with early signs of necroptotic cell death were evident. Intriguingly, cytoplasmic vacuolization, late-stage necroptotic or autophagic cell death were the main features 48 h after Gx15-070 (1 uM) treatment.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Western blot
Cell Lines T1682 cells
Concentrations 100, 250, 500, 1000 nM
Incubation Time 6 h
Results Gx15-070 induced a progressive reduction of AKT Ser473 and Thr308 phosphorylation and a reduction of p-RPS6 phosphorylation, suggesting inhibition of mTOR pathway, in line with previous reports. Moreover, Gx15-070 induced phosphorylation of AMPKα, a Ser/Thr kinase normally activated when ATP level is reduced.AMPK phosphorylation and LC3B cleavage appeared within 1 h after Gx15-070 treatment.

Click to enlarge
Rating
Source Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Viability assay
Cell Lines BM3.3 CD8 T cells
Concentrations 0.1-10uM
Incubation Time
Results T-cell activation induced resistance to Bcl-2 inhibition by ABT-737 (no binding of A1 and Mcl-1) and by Antimycin A (no binding of A1 only), but had no impact on the proapoptotic potency of the pan-Bcl-2 inhibitor obatoclax.

Click to enlarge
Rating
Source Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunostaining
Cell Lines HUH6 cells
Concentrations 0.1, 0.3 uM
Incubation Time 24 h
Results In HUH6 cells mitochondria with an intact membrane potential were observed in the JC-1 staining in both, control and TNF-a treated cultures (C, D). The number of reddish points indicating active mitochondria decreased when the HUH6 cells were treated with obatoclax and decreased even further when the treatment was performed in combination with TNF-a, which reflects the breakdown of mitochondrial membranes decreased aggregation of JC-1. This was concentration dependent (E-H).

Click to enlarge
Rating
Source BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell proliferation assays
Cell Lines SET-2 cells
Concentrations 1-10000 nM
Incubation Time 72 h
Results Incubation of SET-2 cells with sub-optimal concentrations of the pan-Bcl-2 family protein inhibitor obatoclax in cell proliferation assays lowered the GI 50 of NVP-BSK805 by 3 to 4 fold.

Click to enlarge
Rating
Source Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Clonogenic survival assay
Cell Lines MEF cells
Concentrations 0-300 ng/mL
Incubation Time 24 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Hoechst staining
Cell Lines MDB-MA-231 cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell Viability/Western Blot
Cell Lines Nalm-6 ABT-R cells
Concentrations 5-10 uM
Incubation Time 18 h
Results Nalm-6 ABT-R cells were sensitive to obatoclax; however, Nalm-6 cells were equally sensitive (IC50: 10 umol/L). Reh parental cells (IC50: 5umol/L) were also more sensitive to obatoclax compared with ABT-R cells, as measured by trypan blue exclusion. Mcl-1 protein levels were downregulated following obatoclax treatment. NOXA levels also increased, however these changes did not correlate with cell death.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us